Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial ; volume:3 ; number:2 ; day:19 ; month:4 ; year:2011 ; pages:1-11 ; date:4.2011
Alzheimer's research & therapy ; 3, Heft 2 (19.4.2011), 1-11, 4.2011
- Urheber
-
Piette, François
- Beteiligte Personen und Organisationen
-
Belmin, Joël
Vincent, Hélène
Schmidt, Nicolas
Pariel, Sylvie
Verny, Marc
Marquis, Caroline
Mely, Jean
Hugonot-Diener, Laurence
Kinet, Jean-Pierre
Dubreuil, Patrice
Moussy, Alain
Hermine, Olivier
SpringerLink (Online service)
- DOI
-
10.1186/alzrt75
- URN
-
urn:nbn:de:1111-2016073131260
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Piette, François
- Belmin, Joël
- Vincent, Hélène
- Schmidt, Nicolas
- Pariel, Sylvie
- Verny, Marc
- Marquis, Caroline
- Mely, Jean
- Hugonot-Diener, Laurence
- Kinet, Jean-Pierre
- Dubreuil, Patrice
- Moussy, Alain
- Hermine, Olivier
- SpringerLink (Online service)
Ähnliche Objekte (12)
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
Zinc adjunct therapy reduces case fatality in severe childhood pneumonia: a randomized double blind placebo-controlled trial
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial
Moderate to severe HIV-associated neurocognitive impairment : A randomized placebo-controlled trial of lithium
Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
Aesthetic Correction of Mild-to-Moderate Blepharoptosis Among Asians: The Bridge Technique
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
Zinc adjunct therapy reduces case fatality in severe childhood pneumonia: a randomized double blind placebo-controlled trial
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial
Moderate to severe HIV-associated neurocognitive impairment : A randomized placebo-controlled trial of lithium
Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
Aesthetic Correction of Mild-to-Moderate Blepharoptosis Among Asians: The Bridge Technique
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Correction: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Adjunct therapy with probiotics for chronic urticaria in children: randomised placebo-controlled trial
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
Efficacy of sodium butyrate adjunct therapy in shigellosis: a randomized, double-blind, placebo-controlled clinical trial
Zinc adjunct therapy reduces case fatality in severe childhood pneumonia: a randomized double blind placebo-controlled trial
Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial
Moderate to severe HIV-associated neurocognitive impairment : A randomized placebo-controlled trial of lithium
Adjunct prednisone in community-acquired pneumonia: 180-day outcome of a multicentre, double-blind, randomized, placebo-controlled trial
Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial